Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 3/2015

01-03-2015 | Original Article

Association of high CD4-positive T cell infiltration with mutations in HLA class II-regulatory genes in microsatellite-unstable colorectal cancer

Authors: Eva-Maria Surmann, Anita Y. Voigt, Sara Michel, Kathrin Bauer, Miriam Reuschenbach, Soldano Ferrone, Magnus von Knebel Doeberitz, Matthias Kloor

Published in: Cancer Immunology, Immunotherapy | Issue 3/2015

Login to get access

Abstract

Besides being expressed on professional antigen-presenting cells, HLA class II antigens are expressed on various tumors of non-lymphoid origin, including a subset of colorectal cancers (CRC). Information about the regulation of HLA class II antigen expression is important for a better understanding of their role in the interactions between tumor and immune cells. Whether lack of HLA class II antigen expression in tumors reflects the selective immune destruction of HLA class II antigen-expressing tumor cells is unknown. To address this question, we tested whether lack of HLA class II antigen expression in CRC was associated with immune cell infiltration. We selected microsatellite-unstable (MSI-H) CRC, because they show pronounced tumor antigen-specific immune responses and, in a subset of tumors, lack of HLA class II antigen expression due to mutations inactivating HLA class II-regulatory genes. We examined HLA class II antigen expression, mutations in regulatory genes, and CD4-positive T cell infiltration in 69 MSI-H CRC lesions. Mutations in RFX5, CIITA, and RFXAP were found in 13 (28.9 %), 3 (6.7 %), and 1 (2.2 %) out of 45 HLA class II antigen-negative tumors. CD4-positive tumor-infiltrating lymphocyte counts were significantly higher in HLA class II antigen-negative tumors harboring mutations in HLA class II-regulatory genes (107.4 T cells per 0.25 mm2) compared to tumors without mutations (55.5 T cells per 0.25 mm2, p = 0.008). Our results suggest that the outgrowth of tumor cells lacking HLA class II antigen expression due to mutations of regulatory genes is favored in an environment of dense CD4-positive T cell infiltration.
Literature
3.
go back to reference Gutierrez J, Lopez-Nevot MA, Cabrera T, Oliva R, Esquivias J, Ruiz-Cabello F, Garrido F (1987) Class I and II HLA antigen distribution in normal mucosa, adenoma and colon carcinoma: relation with malignancy and invasiveness. Exp Clin Immunogenet 4:144–152PubMed Gutierrez J, Lopez-Nevot MA, Cabrera T, Oliva R, Esquivias J, Ruiz-Cabello F, Garrido F (1987) Class I and II HLA antigen distribution in normal mucosa, adenoma and colon carcinoma: relation with malignancy and invasiveness. Exp Clin Immunogenet 4:144–152PubMed
4.
go back to reference Cabrera T, Ruiz-Cabello F, Garrido F (1995) Biological implications of HLA-DR expression in tumours. Scand J Immunol 41:398–406CrossRefPubMed Cabrera T, Ruiz-Cabello F, Garrido F (1995) Biological implications of HLA-DR expression in tumours. Scand J Immunol 41:398–406CrossRefPubMed
6.
go back to reference Morita M, Tanaka K, Kawanishi H, Tsuji M, Ookusa T, Takada H, Okamura A, Hioki K (1995) Immunohistochemically demonstrated expression of HLA-DR antigen in colorectal adenocarcinomas and its relation to clinicopathological features. J Surg Oncol 59:233–238. doi:10.1002/jso.2930590407 CrossRefPubMed Morita M, Tanaka K, Kawanishi H, Tsuji M, Ookusa T, Takada H, Okamura A, Hioki K (1995) Immunohistochemically demonstrated expression of HLA-DR antigen in colorectal adenocarcinomas and its relation to clinicopathological features. J Surg Oncol 59:233–238. doi:10.​1002/​jso.​2930590407 CrossRefPubMed
7.
go back to reference Walsh MD, Dent OF, Young JP et al (2009) HLA-DR expression is associated with better prognosis in sporadic Australian clinicopathological Stage C colorectal cancers. Int J Cancer 125:1231–1237. doi:10.1002/ijc.24484 CrossRefPubMed Walsh MD, Dent OF, Young JP et al (2009) HLA-DR expression is associated with better prognosis in sporadic Australian clinicopathological Stage C colorectal cancers. Int J Cancer 125:1231–1237. doi:10.​1002/​ijc.​24484 CrossRefPubMed
8.
go back to reference LeibundGut-Landmann S, Waldburger JM, Krawczyk M, Otten LA, Suter T, Fontana A, Acha-Orbea H, Reith W (2004) Mini-review: specificity and expression of CIITA, the master regulator of MHC class II genes. Eur J Immunol 34:1513–1525. doi:10.1002/eji.200424964 CrossRefPubMed LeibundGut-Landmann S, Waldburger JM, Krawczyk M, Otten LA, Suter T, Fontana A, Acha-Orbea H, Reith W (2004) Mini-review: specificity and expression of CIITA, the master regulator of MHC class II genes. Eur J Immunol 34:1513–1525. doi:10.​1002/​eji.​200424964 CrossRefPubMed
9.
go back to reference Michel S, Linnebacher M, Alcaniz J et al (2010) Lack of HLA class II antigen expression in microsatellite unstable colorectal carcinomas is caused by mutations in HLA class II regulatory genes. Int J Cancer 127:889–898. doi:10.1002/ijc.25106 PubMedCentralPubMed Michel S, Linnebacher M, Alcaniz J et al (2010) Lack of HLA class II antigen expression in microsatellite unstable colorectal carcinomas is caused by mutations in HLA class II regulatory genes. Int J Cancer 127:889–898. doi:10.​1002/​ijc.​25106 PubMedCentralPubMed
10.
go back to reference Satoh A, Toyota M, Ikeda H et al (2004) Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric cancer cells. Oncogene 23:8876–8886. doi:10.1038/sj.onc.1208144 CrossRefPubMed Satoh A, Toyota M, Ikeda H et al (2004) Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric cancer cells. Oncogene 23:8876–8886. doi:10.​1038/​sj.​onc.​1208144 CrossRefPubMed
12.
go back to reference Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M (1993) Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363:558–561. doi:10.1038/363558a0 CrossRefPubMed Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M (1993) Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363:558–561. doi:10.​1038/​363558a0 CrossRefPubMed
15.
go back to reference Schwitalle Y, Kloor M, Eiermann S, Linnebacher M, Kienle P, Knaebel HP, Tariverdian M, Benner A, von Knebel Doeberitz M (2008) Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology 134:988–997. doi:10.1053/j.gastro.2008.01.015 CrossRefPubMed Schwitalle Y, Kloor M, Eiermann S, Linnebacher M, Kienle P, Knaebel HP, Tariverdian M, Benner A, von Knebel Doeberitz M (2008) Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology 134:988–997. doi:10.​1053/​j.​gastro.​2008.​01.​015 CrossRefPubMed
17.
go back to reference Linnebacher M, Gebert J, Rudy W, Woerner S, Yuan YP, Bork P, von Knebel Doeberitz M (2001) Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens. Int J Cancer 93:6–11. doi:10.1002/ijc.1298 CrossRefPubMed Linnebacher M, Gebert J, Rudy W, Woerner S, Yuan YP, Bork P, von Knebel Doeberitz M (2001) Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens. Int J Cancer 93:6–11. doi:10.​1002/​ijc.​1298 CrossRefPubMed
20.
go back to reference Buckowitz A, Knaebel HP, Benner A, Blaker H, Gebert J, Kienle P, von Knebel Doeberitz M, Kloor M (2005) Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases. Br J Cancer 92:1746–1753. doi:10.1038/sj.bjc.6602534 CrossRefPubMedCentralPubMed Buckowitz A, Knaebel HP, Benner A, Blaker H, Gebert J, Kienle P, von Knebel Doeberitz M, Kloor M (2005) Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases. Br J Cancer 92:1746–1753. doi:10.​1038/​sj.​bjc.​6602534 CrossRefPubMedCentralPubMed
21.
go back to reference Woerner SM, Kloor M, von Knebel Doeberitz M, Gebert JF (2006) Microsatellite instability in the development of DNA mismatch repair deficient tumors. Cancer Biomark 2:69–86PubMed Woerner SM, Kloor M, von Knebel Doeberitz M, Gebert JF (2006) Microsatellite instability in the development of DNA mismatch repair deficient tumors. Cancer Biomark 2:69–86PubMed
22.
go back to reference Woerner SM, Yuan YP, Benner A, Korff S, von Knebel Doeberitz M, Bork P (2010) SelTarbase, a database of human mononucleotide-microsatellite mutations and their potential impact to tumorigenesis and immunology. Nucleic Acids Res 38:D682–D689. doi:10.1093/nar/gkp839 CrossRefPubMedCentralPubMed Woerner SM, Yuan YP, Benner A, Korff S, von Knebel Doeberitz M, Bork P (2010) SelTarbase, a database of human mononucleotide-microsatellite mutations and their potential impact to tumorigenesis and immunology. Nucleic Acids Res 38:D682–D689. doi:10.​1093/​nar/​gkp839 CrossRefPubMedCentralPubMed
23.
go back to reference Bicknell DC, Kaklamanis L, Hampson R, Bodmer WF, Karran P (1996) Selection for beta 2-microglobulin mutation in mismatch repair-defective colorectal carcinomas. Curr Biol 6:1695–1697CrossRefPubMed Bicknell DC, Kaklamanis L, Hampson R, Bodmer WF, Karran P (1996) Selection for beta 2-microglobulin mutation in mismatch repair-defective colorectal carcinomas. Curr Biol 6:1695–1697CrossRefPubMed
26.
go back to reference Boland CR, Thibodeau SN, Hamilton SR et al (1998) A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58:5248–5257PubMed Boland CR, Thibodeau SN, Hamilton SR et al (1998) A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58:5248–5257PubMed
27.
28.
29.
go back to reference Temponi M, Kageshita T, Perosa F, Ono R, Okada H, Ferrone S (1989) Purification of murine IgG monoclonal antibodies by precipitation with caprylic acid: comparison with other methods of purification. Hybridoma 8:85–95. doi:10.1089/hyb.1989.8.85 CrossRefPubMed Temponi M, Kageshita T, Perosa F, Ono R, Okada H, Ferrone S (1989) Purification of murine IgG monoclonal antibodies by precipitation with caprylic acid: comparison with other methods of purification. Hybridoma 8:85–95. doi:10.​1089/​hyb.​1989.​8.​85 CrossRefPubMed
30.
go back to reference Lee B, Sharron M, Montaner LJ, Weissman D, Doms RW (1999) Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc Natl Acad Sci USA 96:5215–5220CrossRefPubMedCentralPubMed Lee B, Sharron M, Montaner LJ, Weissman D, Doms RW (1999) Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc Natl Acad Sci USA 96:5215–5220CrossRefPubMedCentralPubMed
31.
go back to reference Wood GS, Warner NL, Warnke RA (1983) Anti-Leu-3/T4 antibodies react with cells of monocyte/macrophage and Langerhans lineage. J Immunol 131:212–216PubMed Wood GS, Warner NL, Warnke RA (1983) Anti-Leu-3/T4 antibodies react with cells of monocyte/macrophage and Langerhans lineage. J Immunol 131:212–216PubMed
32.
33.
go back to reference Finke JH, Rayman P, Alexander J, Edinger M, Tubbs RR, Connelly R, Pontes E, Bukowski R (1990) Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma. Cancer Res 50:2363–2370PubMed Finke JH, Rayman P, Alexander J, Edinger M, Tubbs RR, Connelly R, Pontes E, Bukowski R (1990) Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma. Cancer Res 50:2363–2370PubMed
35.
go back to reference Williams NS, Engelhard VH (1996) Identification of a population of CD4 + CTL that utilizes a perforin- rather than a Fas ligand-dependent cytotoxic mechanism. J Immunol 156:153–159PubMed Williams NS, Engelhard VH (1996) Identification of a population of CD4 + CTL that utilizes a perforin- rather than a Fas ligand-dependent cytotoxic mechanism. J Immunol 156:153–159PubMed
38.
go back to reference de Miranda NF, Goudkade D, Jordanova ES, Tops CM, Hes FJ, Vasen HF, van Wezel T, Morreau H (2012) Infiltration of Lynch colorectal cancers by activated immune cells associates with early staging of the primary tumor and absence of lymph node metastases. Clin Cancer Res 18:1237–1245. doi:10.1158/1078-0432.CCR-11-1997 CrossRefPubMed de Miranda NF, Goudkade D, Jordanova ES, Tops CM, Hes FJ, Vasen HF, van Wezel T, Morreau H (2012) Infiltration of Lynch colorectal cancers by activated immune cells associates with early staging of the primary tumor and absence of lymph node metastases. Clin Cancer Res 18:1237–1245. doi:10.​1158/​1078-0432.​CCR-11-1997 CrossRefPubMed
Metadata
Title
Association of high CD4-positive T cell infiltration with mutations in HLA class II-regulatory genes in microsatellite-unstable colorectal cancer
Authors
Eva-Maria Surmann
Anita Y. Voigt
Sara Michel
Kathrin Bauer
Miriam Reuschenbach
Soldano Ferrone
Magnus von Knebel Doeberitz
Matthias Kloor
Publication date
01-03-2015
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 3/2015
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-014-1638-4

Other articles of this Issue 3/2015

Cancer Immunology, Immunotherapy 3/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine